Qingyuan Zhang

机构：Harbin Medical University, Third Affiliated Hospital of Harbin Medical University · ORCID：0000-0001-8116-5293

发表论文 91 篇 · 总被引 1924 次 · h-index 18

代表论文

• Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial (2024 · The Lancet · 被引 166)
• Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial (2025 · Nature Cancer · 被引 52)
• Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort (2025 · Nature Communications · 被引 15)
• Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial (2025 · Cancer · 被引 11)
• Efficacy and safety of KN026 and docetaxel for HER2‐positive breast cancer: a phase II clinical trial (2025 · 癌症：英文版 · 被引 9)
• Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study (2025 · Nature Communications · 被引 7)